Stock Scorecard
Stock Summary for Kamada Ltd (KMDA) - $5.10 as of 4/23/2024 4:05:57 AM EST
Total Score
18 out of 29
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for KMDA
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KMDA
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KMDA
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for KMDA
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for KMDA
Financial Details for KMDA
Company Overview |
|
---|---|
Ticker | KMDA |
Company Name | Kamada Ltd |
Country | USA |
Description | Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/22/2024 |
Stock Price History |
|
Last Day Price | 5.10 |
Last Day Price Updated | 4/23/2024 4:05:57 AM EST |
Last Day Volume | 7,991 |
Average Daily Volume | 21,488 |
52-Week High | 6.53 |
52-Week Low | 4.08 |
Last Price to 52 Week Low | 25.00% |
Valuation Measures |
|
Trailing PE | 33.67 |
Industry PE | 99.84 |
Sector PE | 60.50 |
5-Year Average PE | -30.88 |
Free Cash Flow Ratio | 5.31 |
Industry Free Cash Flow Ratio | 12.59 |
Sector Free Cash Flow Ratio | 29.99 |
Current Ratio Most Recent Quarter | 3.43 |
Total Cash Per Share | 0.96 |
Book Value Per Share Most Recent Quarter | 4.24 |
Price to Book Ratio | 1.22 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 2.08 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 57,480,000 |
Market Capitalization | 293,148,000 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 22.70% |
Annual Earnings Growth | 456.92% |
Reported EPS 12 Trailing Months | 0.15 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 0.15 |
Net Income Twelve Trailing Months | 8,284,000 |
Net Income Past Year | 8,284,000 |
Net Income Prior Year | -2,321,000 |
Quarterly Revenue Growth YOY | -19.80% |
5-Year Revenue Growth | 4.81% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 55,180,507 |
Total Cash Past Year | 55,180,507 |
Total Cash Prior Year | 34,258,000 |
Net Cash Position Most Recent Quarter | 55,180,507 |
Net Cash Position Past Year | 42,217,507 |
Long Term Debt Past Year | 12,963,000 |
Long Term Debt Prior Year | 12,963,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 0.95 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 242,001,450 |
Total Stockholder Equity Prior Year | 176,020,000 |
Total Stockholder Equity Most Recent Quarter | 242,001,450 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.20 |
MACD Signal | -0.18 |
20-Day Bollinger Lower Band | 5.05 |
20-Day Bollinger Middle Band | 5.78 |
20-Day Bollinger Upper Band | 6.51 |
Beta | 0.24 |
RSI | 38.19 |
50-Day SMA | 5.34 |
200-Day SMA | 5.76 |
System |
|
Modified | 4/23/2024 4:06:43 AM EST |